GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CG Invites Co 083790.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

784

-2.61%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CG Invites Co

Its shares trade on KOSDAQ under the ticker 083790.KQ. It has been listed since 6 January 2006. In the fiscal year to 31 December 2025, it reported revenue of ₩27.39bn and a net loss of ₩3.52bn. At that date it held total assets of ₩224.11bn and shareholders' equity of ₩105.15bn.

CrystalGenomics, Inc. engages in the discovery and development of novel therapeutics. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-01-06. The firm operates through three segments. The fFinished Pharmaceuticals Manufacturing segment is engaged in the manufacture and sale of finished pharmaceuticals. The Pharmaceutical R&D Division is engaged in the provision of clinical trial analysis and technical services and the sale of new drugs. The segment also operates in the real estate leasing business. The Others segment engages in the manufacture and sale of hot fats and other household items.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
6 Jan 2006
Website
cgxinc.com ↗

Leadership

Pay as last reported

  • Mr. Yin Cheol JungCo-Chief Executive Officer, Director, since 2024
  • Su Yeon OhCo-Chief Executive Officer, Director, since 2024
  • Mr. Yeong Jun YooInternal Auditor
  • Ms. Gyeong Suk ChoDirector
  • Mr. Seung Hyeon ChoiDirector
  • Mr. Jin Gon KimDirector
  • Yong Gyu ShinDirector
  • Mr. Jin Wu LeeNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • CrystalGenomics develops novel therapeutics in the Biotechnology sector.
  • The company manufactures finished pharmaceuticals in the Finished Pharmaceuticals Manufacturing segment.
  • CrystalGenomics operates in the Real Estate Leasing business segment.

Weaknesses

  • The company's Pharmaceutical R&D Division provides clinical trial analysis services.
  • The Others segment manufactures hot fats and household items.
  • CrystalGenomics has a listing date of 6 January 2006.

Opportunities

  • The Biotechnology sector offers growth in novel therapeutics development.
  • The Finished Pharmaceuticals Manufacturing segment can expand its market reach.
  • The Real Estate Leasing business segment presents new leasing opportunities.

Threats

  • The Others segment's hot fats and household items face market competition.
  • The Pharmaceutical R&D Division's clinical trial analysis services may face regulatory challenges.
  • CrystalGenomics' listing date of 6 January 2006 may impact investor interest.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.